Autologous and allogenic HSCT in NHL(DLBC) and HL (classic)

Non Hodgkin Lymphoma (DLBCL) Key Points: In the RTX era, auto-HSCT is generally not recommended as part of first-line therapy in DLBCL although recent data on PET-guided auto-HSCT are promis- ing. Auto-HSCT is still the standard of care for those DLBCL patients with chemosensitive first relapse. Results of auto-HSCT might improved with better selection of patients (e.g., including PET imaging for patient selection), and improved salvage strategies results. Allo-HSCT is the only curative treatment option for patients with refractory disease and those relapsing after auto- HSCT. Patients with early relapse (< 12 months after first-line treatment) should be considered.Haploidentical transplants may substitute for unrelated donor transplants in the near future. New drugs have not really changed the treatment algorithm for DLBCL. The role of CAR T cells is under study.Classic Hodgkin lymphoma Key Points: Auto-HSCT is still the standard of care for those patients with primary refrac- tory/chemosensitive first relapse. Results of auto-HSCT might improve in the future with better selection of patients, improved results of salvage strategies and consolidation treatment in those patients with high risk of relapse after auto-HSCT. Allo-HSCT is the only curative treat- ment options for those patients relaps- ing after auto-HSCT. The use of allo-HSCT is being modified by the introduction of haploidentical donors as well as targeted therapies in this setting